257 related articles for article (PubMed ID: 11490159)
41. T-cell recognition of ovarian cancer.
Peoples GE; Schoof DD; Andrews JV; Goedegebuure PS; Eberlein TJ
Surgery; 1993 Aug; 114(2):227-34. PubMed ID: 8342128
[TBL] [Abstract][Full Text] [Related]
42. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
43. Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages.
Rei M; Gonçalves-Sousa N; Lança T; Thompson RG; Mensurado S; Balkwill FR; Kulbe H; Pennington DJ; Silva-Santos B
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3562-70. PubMed ID: 25114209
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
45. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
46. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
[TBL] [Abstract][Full Text] [Related]
47. Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model.
Dou J; Wang Y; Wang J; Zhao F; Li Y; Cao M; Hu W; Hu K; He XF; Chu L; Jiang C; Gu N
Immunobiology; 2009; 214(6):483-92. PubMed ID: 19389515
[TBL] [Abstract][Full Text] [Related]
48. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
[TBL] [Abstract][Full Text] [Related]
49. Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo.
Dubinett SM; Patrone L; Tobias J; Cochran AJ; Wen DR; McBride WH
Cancer Immunol Immunother; 1993; 36(3):156-62. PubMed ID: 8382559
[TBL] [Abstract][Full Text] [Related]
50. Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.
Wang XD; Gao NN; Diao YW; Liu Y; Gao D; Li W; Wan YY; Zhong JJ; Jin GY
World J Gastroenterol; 2015 Jul; 21(26):8052-60. PubMed ID: 26185376
[TBL] [Abstract][Full Text] [Related]
51. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β
Overgaard NH; Principe DR; Schachtschneider KM; Jakobsen JT; Rund LA; Grippo PJ; Schook LB; Jungersen G
Front Immunol; 2018; 9():1301. PubMed ID: 29930558
[TBL] [Abstract][Full Text] [Related]
52. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis.
Wakita D; Sumida K; Iwakura Y; Nishikawa H; Ohkuri T; Chamoto K; Kitamura H; Nishimura T
Eur J Immunol; 2010 Jul; 40(7):1927-37. PubMed ID: 20397212
[TBL] [Abstract][Full Text] [Related]
53. [Experimental and clinical research of cytolytic T lymphocytes specific for hepatocellular carcinoma].
Shen F; Wang H; Xie T
Zhonghua Wai Ke Za Zhi; 1997 Feb; 35(2):95-9. PubMed ID: 10374486
[TBL] [Abstract][Full Text] [Related]
54. Induction of cytotoxic T lymphocytes by CEA peptide-pulsed γδ T-cells isolated from patients with advanced cancer.
Yamasaki A; Onishi H; Morisaki T; Katano M
Anticancer Res; 2011 Jul; 31(7):2419-24. PubMed ID: 21873153
[TBL] [Abstract][Full Text] [Related]
55. Characterization of factors regulating successful immunotherapy using a tumor-specific cytotoxic T lymphocyte clone: role of interleukin-2, cycling pattern of lytic activity and adhesion molecules.
Hammond-McKibben DM; Seth A; Nagarkatti PS; Nagarkatti M
Int J Cancer; 1995 Mar; 60(6):828-36. PubMed ID: 7896454
[TBL] [Abstract][Full Text] [Related]
56. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
Heo DS; Whiteside TL; Kanbour A; Herberman RB
J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
[TBL] [Abstract][Full Text] [Related]
57. [Cytotoxicity of MICA-reactive V delta 1 gamma delta T cells towards epithelial tumor cells].
Qi J; Peng P; Dai MH; Li YH; Cui LX; He W
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):1-7. PubMed ID: 15052765
[TBL] [Abstract][Full Text] [Related]
58. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.
Fox BA; Spiess PJ; Kasid A; Puri R; Mulé JJ; Weber JS; Rosenberg SA
J Biol Response Mod; 1990 Oct; 9(5):499-511. PubMed ID: 2174966
[TBL] [Abstract][Full Text] [Related]
59. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.
Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B
J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489
[TBL] [Abstract][Full Text] [Related]
60. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]